Impact Biomedical Zoar Merger Reverse Split Correction
Analysis based on 8 articles · First reported Sep 15, 2026 · Last updated Sep 15, 2026
The correction removes uncertainty around the merger exchange ratio, which is modestly positive for Impact Biomedical shares as it clarifies shareholder consideration. However, the reverse split and continued-listing concerns keep the stock speculative, with limited broader market impact given the company's small capitalization.
Biomedica. issued a corrected press release on September 14, 2026, fixing the exchange ratio for its proposed merger with Zoar Limited. The original September 11, 2026 release incorrectly stated that Impact stockholders would receive one Zoar Limited share for every four Impact shares; the correct ratio is one Zoar Limited share for every one Impact share held immediately prior to the merger effective time, after giving effect to a reverse stock split. Impact Biomedical's Board of Directors approved a 1-for-12.62 reverse stock split, effective at 12:01 a.m. Eastern Time on September 23, 2026. The stock will continue trading on NYSE American under ticker IBO with a new CUSIP number. Outstanding shares will fall from approximately 107,821,231 to 8,543,679, subject to rounding, with fractional shares rounded up. Stockholders had previously authorized a split range of 1-for-12.48 to 1-for-50 at the CEO's discretion. Equiniti Trust Company will manage the share exchange. The reverse split is intended to support the proposed business combination and continued-listing objectives, though it does not guarantee compliance with NYSE American listing standards or completion of the merger. Zoar Limited has filed a Form F-4 registration statement with the United States — United States Securities and Exchange Commission containing a preliminary proxy statement/prospectus. Upon closing, the combined company is expected to be a pharmaceutical manufacturer focused on active pharmaceutical ingredients, intermediates, formulations, and orphan drug development.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard